Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects - PubMed (original) (raw)

Clinical Trial

Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects

Young-Bum Kim et al. Diabetes. 2002 Feb.

Abstract

Insulin stimulation of phosphatidylinositol (PI) 3-kinase activity is defective in skeletal muscle of type 2 diabetic individuals. We studied the impact of antidiabetic therapy on this defect in type 2 diabetic subjects who failed glyburide treatment by the addition of troglitazone (600 mg/day) or metformin (2,550 mg/day) therapy for 3-4 months. Improvement in glycemic control was similar for the two groups, as indicated by changes in fasting glucose and HbA(1c) levels. Insulin action on whole-body glucose disposal rate (GDR) was determined before and after treatment using the hyperinsulinemic (300 mU x m(-2) x min(-1)) euglycemic (5.0-5.5 mmol/l) clamp technique. Needle biopsies of vastus lateralis muscle were obtained before and after each 3-h insulin infusion. Troglitazone treatment resulted in a 35 +/- 9% improvement in GDR (P < 0.01), which was greater than (P < 0.05) the 22 +/- 13% increase (P < 0.05) after metformin treatment. Neither treatment had any effect on basal insulin receptor substrate-1 (IRS-1)-associated PI 3-kinase activity in muscle. However, insulin stimulation of PI 3-kinase activity was augmented nearly threefold after troglitazone treatment (from 67 +/- 22% stimulation over basal pre-treatment to 211 +/- 62% post-treatment, P < 0.05), whereas metformin had no effect. The troglitazone effect on PI 3-kinase activity was associated with a 46 +/- 22% increase (P < 0.05) in the amount of the p110beta catalytic subunit of PI 3-kinase. Insulin-stimulated Akt activity also increased after troglitazone treatment (from 32 +/- 8 to 107 +/- 32% stimulation, P < 0.05) but was unchanged after metformin therapy. Protein expression of other key insulin signaling molecules (IRS-1, the p85 subunit of PI 3-kinase, and Akt) was unaltered after either treatment. We conclude that the mechanism for the insulin-sensitizing effect of troglitazone, but not metformin, involves enhanced PI 3-kinase pathway activation in skeletal muscle of obese type 2 diabetic subjects.

PubMed Disclaimer

Cited by

Iodine Promotes Glucose Uptake through Akt Phosphorylation and Glut-4 in Adipocytes, but Higher Doses Induce Cytotoxic Effects in Pancreatic Beta Cells.
Arely RJ, Cristian AE, Omar AX, Antonio PJ, Isela SR, Yeimy Mar LR, Xcaret Alexa HD, Omar AH. Arely RJ, et al. Biology (Basel). 2024 Jan 1;13(1):26. doi: 10.3390/biology13010026. Biology (Basel). 2024. PMID: 38248457 Free PMC article.
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age.
Lisco G, Disoteo OE, De Tullio A, De Geronimo V, Giagulli VA, Monzani F, Jirillo E, Cozzi R, Guastamacchia E, De Pergola G, Triggiani V. Lisco G, et al. Nutrients. 2023 Dec 25;16(1):63. doi: 10.3390/nu16010063. Nutrients. 2023. PMID: 38201893 Free PMC article. Review.
Therapeutic vs. Suprapharmacological Metformin Concentrations: Different Effects on Energy Metabolism and Mitochondrial Function in Skeletal Muscle Cells in vitro.
Pavlovic K, Krako Jakovljevic N, Isakovic AM, Ivanovic T, Markovic I, Lalic NM. Pavlovic K, et al. Front Pharmacol. 2022 Jul 6;13:930308. doi: 10.3389/fphar.2022.930308. eCollection 2022. Front Pharmacol. 2022. PMID: 35873556 Free PMC article.
Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport.
Herman R, Kravos NA, Jensterle M, Janež A, Dolžan V. Herman R, et al. Int J Mol Sci. 2022 Jan 23;23(3):1264. doi: 10.3390/ijms23031264. Int J Mol Sci. 2022. PMID: 35163187 Free PMC article. Review.
Metformin prevents endothelial oxidative stress and microvascular insulin resistance during obesity development in male rats.
Liu J, Aylor KW, Chai W, Barrett EJ, Liu Z. Liu J, et al. Am J Physiol Endocrinol Metab. 2022 Mar 1;322(3):E293-E306. doi: 10.1152/ajpendo.00240.2021. Epub 2022 Feb 7. Am J Physiol Endocrinol Metab. 2022. PMID: 35128961 Free PMC article.

Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects - PubMed (original) (raw)